par Habre, Maya;Habre, Samer Bassilios;Kourie Hampig, Raphael 
Référence Immunotherapy, 8, 12, page (1437-1446)
Publication Publié, 2016-12
Référence Immunotherapy, 8, 12, page (1437-1446)
Publication Publié, 2016-12
Article révisé par les pairs
| Résumé : | Immune checkpoint inhibitors (ICI) represent a new revolutionary weapon in the armamentarium of anti-cancer therapies. The side effects of these new agents represent a new challenge for oncologists; they are usually unpredictable and sometimes life threatening, if not managed rapidly and adequately. The most frequent side effects are the dermatologic, but they are usually low grade side effects and consequently easily manageable. Rash, pruritus and vitiligo are the most frequent dermatologic side effects. We aimed in this review to describe first all the dermatologic side effects of ICI according to the subtype of ICI and combination therapies in the clinical trials, then to report all the rare case reports dermatologic side effects, and finally to present the management algorithm of these side effects. |
